[go: up one dir, main page]

PE20181531A1 - Vacuna del virus herpes simple - Google Patents

Vacuna del virus herpes simple

Info

Publication number
PE20181531A1
PE20181531A1 PE2018000600A PE2018000600A PE20181531A1 PE 20181531 A1 PE20181531 A1 PE 20181531A1 PE 2018000600 A PE2018000600 A PE 2018000600A PE 2018000600 A PE2018000600 A PE 2018000600A PE 20181531 A1 PE20181531 A1 PE 20181531A1
Authority
PE
Peru
Prior art keywords
herpes virus
virus vaccine
simple herpes
vaccines
hsv
Prior art date
Application number
PE2018000600A
Other languages
English (en)
Inventor
Giuseppe Ciaramella
Shinu John
Andrew J Bett
Danilo R Casimiro
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of PE20181531A1 publication Critical patent/PE20181531A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La descripcion se relaciona con vacunas de acido ribonucleico (ARN) de virus del herpes simple (VHS), asi como a metodos para utilizar las vacunas y a composiciones que comprenden las vacunas
PE2018000600A 2015-10-22 2016-10-21 Vacuna del virus herpes simple PE20181531A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562245031P 2015-10-22 2015-10-22
US201562245159P 2015-10-22 2015-10-22
US201562247576P 2015-10-28 2015-10-28
US201562248252P 2015-10-29 2015-10-29

Publications (1)

Publication Number Publication Date
PE20181531A1 true PE20181531A1 (es) 2018-09-26

Family

ID=58558127

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000600A PE20181531A1 (es) 2015-10-22 2016-10-21 Vacuna del virus herpes simple

Country Status (19)

Country Link
US (2) US20180303929A1 (es)
EP (1) EP3365009A4 (es)
JP (2) JP2018536023A (es)
KR (1) KR20180096593A (es)
CN (1) CN108472355A (es)
AU (2) AU2016342049B2 (es)
BR (1) BR112018008090A2 (es)
CA (1) CA3002822A1 (es)
CL (1) CL2018001056A1 (es)
CO (1) CO2018005258A2 (es)
EA (1) EA201890999A1 (es)
IL (1) IL258833A (es)
MA (1) MA46024A (es)
MX (1) MX2018004918A (es)
PE (1) PE20181531A1 (es)
PH (1) PH12018500855A1 (es)
SG (1) SG11201803365RA (es)
TN (1) TN2018000155A1 (es)
WO (1) WO2017070623A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3981437T (lt) 2014-04-23 2025-01-10 Modernatx, Inc. Nuleorūgšties vakcinos
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
RS63381B1 (sr) 2015-10-22 2022-08-31 Modernatx Inc Vakcine protiv respiratornih virusa
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
CN117731769A (zh) 2015-10-22 2024-03-22 摩登纳特斯有限公司 用于水痘带状疱疹病毒(vzv)的核酸疫苗
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
MA46240A (fr) 2016-09-14 2019-07-24 Modernatx Inc Compositions d'arn de haute pureté et procédés pour leur préparation
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
MA52262A (fr) 2017-03-15 2020-02-19 Modernatx Inc Vaccin à large spectre contre le virus de la grippe
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
MA49463A (fr) * 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
EP3615060A4 (en) * 2017-04-26 2021-06-09 Merck Sharp & Dohme Corp. HSV ANTIGEN PEPTIDS AND HSV PROTEIN VACCINES
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
EP3668520A4 (en) * 2017-08-17 2021-05-12 The Trustees Of The University Of Pennsylvania Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
JP2022501367A (ja) 2018-09-20 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. 脂質ナノ粒子の調製及びその投与方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN109701008B (zh) * 2019-02-18 2022-06-21 山东兴瑞生物科技有限公司 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
JP2022526089A (ja) 2019-03-11 2022-05-23 モデルナティエックス インコーポレイテッド 流加バッチインビトロ転写プロセス
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
WO2021015987A1 (en) * 2019-07-19 2021-01-28 Merck Sharp & Dohme Corp. Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof
JP2022542032A (ja) * 2019-07-21 2022-09-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 治療用ウイルスワクチン
WO2021197589A1 (en) * 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
WO2022006368A2 (en) 2020-07-02 2022-01-06 Life Technologies Corporation Trinucleotide cap analogs, preparation and uses thereof
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
AU2022233957A1 (en) * 2021-03-11 2023-10-12 Redbiotec Ag Vaccine compositions and methods for treating hsv
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
JP2024538489A (ja) 2021-09-03 2024-10-23 キュアバック エスイー 核酸を送達するための新規な脂質ナノ粒子
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
EP4444345A2 (en) 2021-12-08 2024-10-16 ModernaTX, Inc. Herpes simplex virus mrna vaccines
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
CA3242744A1 (en) * 2022-01-27 2023-08-03 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for the administration of herpes simplex virus antigens and associated methods
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4531902A1 (en) 2022-05-25 2025-04-09 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
CN118217388A (zh) * 2022-12-19 2024-06-21 南京奥罗生物科技有限公司 单纯疱疹病毒疫苗及其应用
WO2024163465A1 (en) 2023-01-30 2024-08-08 Modernatx, Inc. Epstein-barr virus mrna vaccines
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024215721A1 (en) 2023-04-10 2024-10-17 Modernatx, Inc. Lyme disease vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025030097A2 (en) * 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025171082A1 (en) * 2024-02-06 2025-08-14 Board Of Regents, The University Of Texas System Prefusion-stabilized hsv2 gb proteins
WO2025259931A1 (en) 2024-06-14 2025-12-18 Orbital Therapeutics, Inc. Compositions and methods for rna circularization
WO2026006203A2 (en) 2024-06-24 2026-01-02 Orbital Therapeutics, Inc. Compositions and methods for making circular rna
WO2026015882A1 (en) * 2024-07-12 2026-01-15 BioNTech SE Hsv antigen fragments and related methods

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1993001301A1 (en) * 1991-07-05 1993-01-21 The Penn State Research Foundation Mutant antiviral regulatory proteins
GB9406498D0 (en) * 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
US7094767B2 (en) * 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
JP2001508649A (ja) * 1996-11-04 2001-07-03 スミスクライン・ビーチャム・コーポレイション ２型単純ヘルペスウイルス由来の新規コーディング配列
WO2001023414A2 (en) * 1999-09-30 2001-04-05 University Of Washington Immunologically significant herpes simplex virus antigens
JP2003535832A (ja) * 2000-06-09 2003-12-02 ブリカス，テニ ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
ES2240745T3 (es) 2001-06-05 2005-10-16 Curevac Gmbh Composicion farmaceutica que contiene un arnm estabilizado y optimizado para la traduccion, adecuada como vacuna y como regenerante de tejidos.
EP1412065A2 (en) 2001-07-27 2004-04-28 President And Fellows Of Harvard College Laminar mixing apparatus and methods
WO2003028657A2 (en) 2001-10-03 2003-04-10 The Johns Hopkins University Compositions for oral gene therapy and methods of using same
AU2003217531A1 (en) 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
KR20060130057A (ko) * 2003-11-21 2006-12-18 알자 코포레이션 절단가능한 ｐｅｇ 표면 변형을 갖는 리포좀-ｄｎａ복합체에 의해 매개되는 유전자 송달
EP1713514B1 (en) 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
EP1742663A2 (en) 2004-04-15 2007-01-17 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
ES2407979T3 (es) 2004-12-10 2013-06-17 Kala Pharmaceuticals, Inc. Copolímeros de bloques de poli(éter-anhídrido) funcionalizados
CA2603853C (en) 2005-04-01 2013-11-19 Intezyne Technologies, Incorporated Polymeric micelles for drug delivery
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
PT2279758E (pt) 2005-06-16 2015-05-27 Nektar Therapeutics Conjugados possuindo uma ligação degradável e reagentes poliméricos úteis na preparação de tais conjugados
US9149543B2 (en) * 2005-12-15 2015-10-06 The Trustees Of The University Of Pennsylvania Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
WO2007098466A2 (en) 2006-02-21 2007-08-30 Nektar Therapeutics Al, Corporation Segmented degradable polymers and conjugates made therefrom
WO2007133807A2 (en) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
NZ572808A (en) * 2006-05-19 2011-11-25 Water And Eliza Hall Inst Of Medical Res Compositions for raising an immune response comprising an antigen and a targeting moiety for lymph-resident dendritic cells
EP2521786B1 (en) * 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
ATE498393T1 (de) 2006-09-08 2011-03-15 Univ Johns Hopkins Zusammensetzungen zur transportintensivierung durch die schleimhaut
JP5452230B2 (ja) 2006-12-21 2014-03-26 ストライカー コーポレイション 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
HUE034775T2 (hu) 2007-09-28 2018-02-28 Pfizer Rákos sejt célzása nanorészecskék alkalmazásával
WO2010005721A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
EP2285350B1 (en) 2008-06-16 2017-11-15 Pfizer Inc Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
JP5622254B2 (ja) 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
EP2496700B1 (en) 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
WO2011084518A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
US20130101609A1 (en) 2010-01-24 2013-04-25 Novartis Ag Irradiated biodegradable polymer microparticles
WO2011106607A2 (en) * 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
WO2011163483A2 (en) 2010-06-25 2011-12-29 Massachusetts Institute Of Technology Polymers for biomaterials and therapeutics
SI4005592T1 (sl) * 2010-07-06 2023-03-31 Glaxosmithkline Biologicals S.A. Virionom podobni dostavni delci za samopodvojene molekule RNA
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
TR201903651T4 (tr) * 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
EP2629760A4 (en) 2010-10-22 2014-04-02 Bind Therapeutics Inc THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT
AU2011323250B2 (en) 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
EP2670443A4 (en) * 2011-01-31 2015-10-14 Univ Pennsylvania FOR NUCLEIC ACID MOLECULAR ENCODING NEW HERPES ANTIGENES, VACCINES THEREOF AND METHOD OF USE THEREOF
WO2012109121A1 (en) 2011-02-07 2012-08-16 Purdue Research Foundation Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
WO2012131106A1 (en) 2011-03-31 2012-10-04 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
WO2012131104A2 (en) 2011-03-31 2012-10-04 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EP4115875A1 (en) * 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
ES2670944T3 (es) 2011-07-21 2018-06-04 Croda International Plc Copolímeros de bloques de poliéter-poliamida ramificados y métodos de preparación y uso de los mismos
CN104024328A (zh) 2011-08-26 2014-09-03 箭头研究公司 用于体内核酸递送的聚(乙烯基酯)聚合物
CN103930135A (zh) 2011-08-31 2014-07-16 马林克罗特有限公司 使用h-膦酸酯的纳米颗粒peg修饰
WO2013044219A1 (en) 2011-09-22 2013-03-28 Bind Biosciences Methods of treating cancers with therapeutic nanoparticles
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
MX2014004214A (es) * 2011-10-11 2014-05-07 Novartis Ag Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
AU2012325997C1 (en) 2011-10-18 2018-07-05 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
EP2771319B1 (en) 2011-10-27 2022-03-02 Massachusetts Institute of Technology Amino acid derivatives functionalized on the n- terminal capable of forming drug incapsulating microspheres
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
CA3018046A1 (en) * 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
AU2013209452B2 (en) 2012-01-19 2015-11-05 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
WO2013113326A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP3312155B1 (en) 2012-02-03 2020-08-05 Rutgers, The State University of New Jersey Polymeric biomaterials derived from phenolic monomers and their medical uses
US20150337068A1 (en) 2012-02-10 2015-11-26 Karl K Berggren Preparation, purification and use of high-x diblock copolymers
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
JP2015513913A (ja) * 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
BR112014030677A2 (pt) * 2012-06-08 2022-07-19 Shire Human Genetic Therapies distribuição pulmonar de mrna para células-alvo não-pulmonares
WO2014093924A1 (en) * 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
ES2968649T3 (es) * 2012-12-07 2024-05-13 Translate Bio Inc Nanopartículas lipídicas para la administración de ARNm en los pulmones
LT2970456T (lt) * 2013-03-14 2021-08-10 Translate Bio, Inc. Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP4614148A3 (en) * 2013-03-15 2025-12-17 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
TW201534578A (zh) * 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
LT3981437T (lt) * 2014-04-23 2025-01-10 Modernatx, Inc. Nuleorūgšties vakcinos
WO2018226638A1 (en) * 2017-06-05 2018-12-13 The Brigham And Women's Hospital, Inc. Vero cell lines stably expressing hsv icp0 protein

Also Published As

Publication number Publication date
WO2017070623A1 (en) 2017-04-27
MA46024A (fr) 2019-07-03
CN108472355A (zh) 2018-08-31
AU2023216825A1 (en) 2023-09-07
PH12018500855A1 (en) 2018-10-29
EA201890999A1 (ru) 2018-12-28
CL2018001056A1 (es) 2018-10-19
AU2016342049A1 (en) 2018-06-07
SG11201803365RA (en) 2018-05-30
IL258833A (en) 2018-06-28
TN2018000155A1 (en) 2019-10-04
EP3365009A1 (en) 2018-08-29
KR20180096593A (ko) 2018-08-29
MX2018004918A (es) 2019-04-01
CO2018005258A2 (es) 2018-11-22
EP3365009A4 (en) 2019-07-03
CA3002822A1 (en) 2017-04-27
JP2022037134A (ja) 2022-03-08
AU2016342049B2 (en) 2023-05-18
US20240173400A1 (en) 2024-05-30
US20180303929A1 (en) 2018-10-25
BR112018008090A2 (pt) 2018-11-13
JP2018536023A (ja) 2018-12-06

Similar Documents

Publication Publication Date Title
PE20181531A1 (es) Vacuna del virus herpes simple
PE20181530A1 (es) Vacuna de virus sincitial respiratorio
CY1125368T1 (el) Εμβολια κατα των ιων του αναπνευστικου συστηματος
BR112018008078A2 (pt) vacina de vírus influenza de amplo espectro
PE20181529A1 (es) Vacunas de acido nucleico para el virus varicela-zoster (vzv)
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
NI201700128A (es) Composiciones de acido obeticolico y metodos de uso.
BR112016024644A2 (pt) vacinas de ácido nucleico
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
MX368655B (es) Variantes de glucoamilasa y polinucleótidos que las codifican.
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
BR112016018654A2 (pt) Composições de silicato estabilizadas e seu uso como composições antiperspirantes
MX2021010060A (es) Produccion de virus en huevos aviares.
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos
CL2021001708A1 (es) Métodos para formar poliplejos
AR106464A1 (es) Vacuna de virus sincitial respiratorio
AR105431A1 (es) Vacunas para enfermedades infecciosas
AR102161A1 (es) Procesos para preparar 2,5-diclorofenol
TH1601002827B (th) ระบบการให้วัคซีนสำหรับทำการจัดส่งวัคซีนไปยังสัตว์ปีกประเภทไก่วัยรุ่นเพศเมีย และวิธีการ, อุปกรณ์ และชุดประกอบที่เกี่ยวเนื่อง
TH148817B (th) รีคอมบิแนนท์ไวรัสเริมของนกชนิดมัลติวาเลนต์ และวัคซีนเพื่อสร้างภูมิคุ้มกันสำหรับสปีชีส์ของนก